Table 2.
Current delivery strategies in clinical trials.
| Delivery Strategy | Drug Name | Disease | Company | Clinical Trial Phase | Status | ClinicalTrials.gov ID |
|---|---|---|---|---|---|---|
| Focused ultrasound | Device: NaviFUS Drug: Bevacizumab (Avastin®) |
Recurrent glioblastoma | NaviFUS Corporation | N/A | Recruiting | NCT04446416 |
| Bi-specific antibody (TfR) |
RO7126209 (Brain shuttle gantenerumab) | Mild to moderate Alzheimer’s disease | Hoffmann-La Roche | Phase 1b/2a | Recruiting | NCT04639050 |
| Bi-specific antibody (TfR) |
DNL310 (Enzyme transport vehicle-Iduronate-2-sulfatase fusion, ETV:IDS) | Mucopolysaccharidosis Type II (Hunter syndrome) | Denali Therapeutics Inc. | Phase 1/2 | Recruiting | NCT04251026 |
| Bi-specific antibody (HIR) |
AGT-181, valanafusp alpha (HIRMab-Human alpha-L-iduronidase fusion) | Mucopolysaccharidosis Type I | ArmaGen, Inc. | Phase 1/2 Phase 1/2 |
Completed Completed |
NCT03053089 NCT03071341 |
N/A = not applicable; TfR = transferrin receptor; HIR = human insulin receptor.